공고 • Feb 11
Q BioMed Inc.'s Chemotherapeutic Uttroside B Receives Notice of Allowance for Patent from United States Patent Office Q BioMed Inc. announced asset Uttroside B - is expected to receive a patent in the United States, adding to the already issued patents in Korea, Canada and Japan. In addition, recent results from pre-clinical pharmacokinetic testing have been very encouraging and the data supports advancing the program. Uttroside B shows tremendous value in the Liver Cancer Market. Uttroside B has also received Orphan Drug designation from the FDA. In early pre-clinical investigation Q BioMed's Uttroside-B showed ten times the cytotoxicity against HCC, which is the toxicity caused due to the action of the chemotherapeutic agent on living cancer cells, as compared to the current standard of care drug at the time. Currently, there are only two approved first-line mono therapies and a combination first-line therapy for HCC. Challenges with current treatments include patients becoming resistant to the specific drugs, adverse side effects, and high costs. 공고 • Oct 18
Q BioMed Inc. announced delayed 10-Q filing On 10/17/2022, Q BioMed Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공고 • Sep 28
Q BioMed Inc. Announces Issuance of Patent for Groundbreaking Gdf15 Biomarker Q BioMed Inc. announced receipt of a European Certificate of Grant for GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 licensed from the Washington University in St. Louis. Determining the severity of glaucoma using this biomarker will aid in treatment decisions for patients diagnosed with, and being treated for, glaucoma. Glaucoma is a group of diseases that damage the eye's optic nerve and can result in vision loss and blindness. However, with early detection and treatment, the eyes can be protected against serious vision loss. Currently, treatment for glaucoma is decided based on intraocular pressure (IOP) and perimetry. However, IOP has a huge variation from patient to patient and perimetry is a subjective test. Thus, a biomarker to aid in treatment decisions for glaucoma is needed. Currently, no single examination or diagnostic test is able to accurately predict disease progression. Accurate monitoring for disease progression is critical to preserve visual function in glaucoma patients, physicians only have surrogate measures to evaluate glaucomatous neurodegeneration. GDF15 represents an attractive biomarker for glaucoma with distinct advantages, including early detection, over conventional clinical tests and has the potential to be a first-in-class diagnostic test. GDF15 was discovered by Dr. Rajendra Apte, the Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences at Washington University School of Medicine.Q BioMed and its technology partner Mannin Research Inc. are currently developing therapeutics with novel mechanisms of action, to treat Primary Open-Angle Glaucoma. By offering both a diagnostic and a therapeutic, Q BioMed and Mannin are addressing the needs of both patients and physicians, as well as bringing innovation to the global glaucoma market estimated to affect over 100 million patients. Glaucoma is one of the leading causes of blindness worldwide. In 2017, researchers at Washington University School of Medicine in St. Louis identified the GDF15 biomarker, showing that it could predict damage to cells in the eye and be used to monitor severity and progression of glaucoma and facilitate treatment decisions and their effectiveness. Growth Differentiation Factor 15 is a member of the Transforming Growth Factor superfamily and was recently identified as a novel and promising biomarker for glaucoma, and its expression correlated with disease severity and progression. GDF15 has been validated in human patients with glaucoma. Beyond reduction of intraocular pressure, the desired goal of any glaucoma therapeutic is neuroprotection, or to be more specific, protection and survival of retinal ganglion cells. 공고 • Jul 16
Q BioMed Inc. announced delayed 10-Q filing On 07/15/2022, Q BioMed Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공고 • Sep 24
Q Biomed Inc. Updates on Covid-19 Therapeutic Development and Clinical Trials - Man-19 Therapeutic Program Heading to Clinical Trial in Early 2022 Q BioMed Inc. provide an update on its partner asset MAN-19 for the treatment of Acute Respiratory Distress Syndrome, a condition caused by viral infections in the lungs including COVID-19. The MAN-19 therapeutic is a recombinant fusion protein that treats the patient, instead of targeting the virus. It is not a cure for COVID, but it strengthens a patient's blood vessels and protects them against ARDS, breathing problems, sepsis and other infections that may cause the body's organs to begin shutting down. It is designed to keep COVID patients out of the ICU and off a ventilator. Initial manufacturing and preclinical testing has shown promise, and pending upcoming toxicology testing, the drug is poised for clinical trials to start in 2022. If the drug proves both safe and effective, goal is to have it available for use by patients by early 2023. The market for this kind of treatment in the current pandemic climate is substantial and global. COVID-19 is not going away any time soon. As a result, there is a need to develop more effective treatments. QBioMed believes that licensing and milestone revenue opportunities for this and related indications in kidney and ophthalmological diseases are possible in the next few months. Conservative estimates based on milestones could reach $200 million over the next 24 months. Partnering with other companies in Canada and Europe, and with the support of what is expected to be more than $20 million USD in funding from Q BioMed and other non-dilutive sources, has resulted in an accelerated drug development timeline. Q BioMed has committed approximately $10 million to the development of the Tie2 platform in exchange for a 50% residual interest in any profits generated from the sale or sub-licensing of the assets, including other candidates for diseases such: glaucoma, kidney diseases, and cardiovascular disease. 공고 • Aug 25
Q Biomed Inc.'s Chemotherapeutic Uttroside B Receives Notice of Allowance for Patent in South Korea and Shows Positive Results in Initial Pre-Clinical Testing Q BioMed Inc. is expected to receive a patent in Korea, adding to the already issued patents in Canada and Japan. In addition, recent results from pre-clinical pharmacokinetic testing have been very encouraging and the data supports advancing the program. Uttroside B shows tremendous value in the Liver Cancer Market. 공고 • Mar 03
Q Biomed Awards Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs Q BioMed Inc. announced that it has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injection, USP) to be included on the Federal Supply Schedule ("FSS"). The agreement provides U.S. veterans and other federal government agencies access to Strontium89 for eligible patients. The final FSS contract is effective March 1, 2021 and has a five-year term. The FSS contract will extend access to Strontium89 to over nine million VA beneficiaries and others within the federal system. Veterans are at higher risk for prostate, breast, and lung cancer, the three most common cancers treated with Strontium89 if they become painfully metastatic to the bone. In fact, prostate cancer rates in the military are twice those in the general population and military personnel were found to be nearly 40 percent more likely to develop breast cancer[2]. Now these patients will be able to benefit from Strontium89 treatment for their metastatic bone pain. Q BioMed is preparing commercially to serve the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) with activities that include a VA sales force, formulary and market access, medical education, and marketing. Efforts will begin in March 2021 and build throughout the year as the FSS agreement is translated to clinical use. 공고 • Feb 02
Q BioMed Inc. Expands Strontium89 Reach Through Agreement with UroGPO Q BioMed Inc. announced that it has been awarded a contract with UroGPO. Through the partnership, UroGPO will support the establishment of Strontium89 (Strontium Chloride Sr-89 Injection, USP) as an added radionuclide therapeutic choice. Strontium89 will be offered to UroGPO urology offices that treat patients with painful bone metastases from prostate and other urological cancers. Studies indicate prostate cancer has the higher risk of bone metastasis, with 8 out of 10 metastatic cases spreading to bone. In the Strontium89 pivotal trial, as many as 79% of patients had pain relief with Strontium89, and twice as many patients treated with Strontium89 had no pain for 3 months compared with placebo. Further, new pain sites were less frequent in patients treated with Strontium89. Strontium89 is administered once every 3 months via injection, and patients can be re-treated if needed. Strontium Chloride Sr-89 Injection, USP is indicated for the relief of bone pain in patients with painful skeletal metastases. The presence of bone metastases should be confirmed prior to therapy. 공고 • Nov 18
Q BioMed's Uttroside-B Receives U.S. Patent in Treatment of Liver Cancer Q BioMed Inc. announces that it has received a patent from the U.S. Patent and Trademark Office for its Uttrocide-B molecule. The Patent is titled "Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma". Q BioMed has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology, an Autonomous Institute under the Department of Biotechnology, Government of India and the Oklahoma Medical Research Foundation. The Method Of Use patent covers the use of a novel pharmaceutical for the treatment of hepatocellular carcinoma. International and additional U.S. claims are currently under prosecution for the technology which addresses a severe unmet need for a safe and effective drug to treat hepatocellular carcinoma (HCC), the most common form of liver cancer. Uttroside-B has shown ten times the potency against HCC as compared to the current standard of care drug in early pre-clinical investigation. Currently, there are only two approved first-line therapies for HCC. Challenges with current treatments include patients becoming resistant to the specific drugs, adverse side effects, and high costs. An estimated 700,000 people are diagnosed with HCC each year, with the global market for liver cancer drugs expected to grow to $3.9 billion by 2027.